Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2282-2290

  Rimm, David L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Nielsen, Torsten O ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Jewell, Scott D ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Rohrer, Daniel C ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Broadwater, Gloria ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Waldman, Frederic ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Mitchell, Kisha A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Singh, Baljit ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Tsongalis, Gregory J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Frankel, Wendy L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Magliocco, Anthony M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Lara, Jonathan F ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Hsi, Eric D ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Bleiweiss, Ira J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Badve, Sunil S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Chen, Beiyun ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Ravdin, Peter M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Schilsky, Richard L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Thor, Ann ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}   Berry, Donald A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r}  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Cancer and Leukemia Group B Pathology Coordinating Office   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h MOUNT SINAI MEDICAL CENTER   (United States)

ⁱ NORRIS COTTON CANCER CENTER   (United States)

^j SAINT BARNABAS MEDICAL CENTER   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m MAYO CLINIC   (United States)

ⁿ UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p UNIVERSITY OF CHICAGO   (United States)

^q UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^r TOM BAKER CANCER CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN; PACLITAXEL;

BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROL GROUP; DOSAGE SCHEDULE COMPARISON; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL SOCIETY; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REDUNDANCY ANALYSIS; REVIEW; STAINING; STATISTICAL ANALYSIS; SURVIVAL TIME; TISSUE MICROARRAY; VALIDATION PROCESS;

CLINICAL TRIALS AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; SPECIMEN HANDLING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79957958114     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2023     Document Type: Review

References (22)

1. Wan WH, Fortuna MB, Furmanski P: A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 103:121-129, 1987 (Pubitemid 17139428)
2. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998 (Pubitemid 28331029)
3. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005 (Pubitemid 41258223)
4. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003 (Pubitemid 46594124)
5. Berry D, Thor A, Jewell S: Benefits of adding paclitaxel to adjuvant doxorubicin/cyclophosphamide depending on HER2 & ER status: Analysis of tumor tissue microarrays and immunohistochemistry in CALGB 9344 (Intergroup 0148). Cancer Res 69:606, 2009 (suppl 24; abstr)
6. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
7. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
8. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York, NY, John Wiley & Sons, 1987
9. Yang XR, Charette LA, Garcia-Closas M, et al: Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma. Diagn Mol Pathol 15:157-161, 2006 (Pubitemid 44325477)
10. Hewitt SM: Tissue microarrays as a tool in the discovery and validation of tumor markers. Methods Mol Biol 520:151-161, 2009
11. Anagnostou VK, Lowery FJ, Syrigos KN, et al: Quantitative evaluation of protein expression as a function of tissue microarray core diameter: Is a large (1.5 mm) core better than a small (0.6 mm) core? Arch Pathol Lab Med 134:613-619, 2010
12. Camp RL, Neumeister V, Rimm DL: A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers. J Clin Oncol 26:5630-5637, 2008
13. McCabe A, Dolled-Filhart M, Camp RL, et al: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97:1808-1815, 2005
14. Sherman ME, Rimm DL, Yang XR, et al: Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population-based analysis. Int J Cancer 121:1079-1085, 2007 (Pubitemid 47101646)
15. Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943-1949, 2000
16. Torhorst J, Bucher C, Kononen J, et al: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249-2256, 2001 (Pubitemid 33104278)
17. Rubin MA, Dunn R, Strawderman M, et al: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312-319, 2002 (Pubitemid 34184454)
18. Moeder CB, Giltnane JM, Harigopal M, et al: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: Tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25:5418-5425, 2007 (Pubitemid 350232218)
19. Fergenbaum JH, Garcia-Closas M, Hewitt SM, et al: Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13:667-672, 2004 (Pubitemid 38737907)
20. DiVito KA, Charette LA, Rimm DL, et al: Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84:1071-1078, 2004 (Pubitemid 39025041)
21. Simon R, Mirlacher M, Sauter G: Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 664:113-126, 2010
22. Porter PL, Barlow WE, Yeh IT, et al: P27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 98:1723-1731, 2006 (Pubitemid 44942710)